ArticleIDCases2022
Visceral leishmaniasis and COVID-19 coinfection - A case report.
Article in IDCases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- An Update on Clinical and Pathogenic Spectra of Leishmaniasis.Expert reviews in molecular medicine · 2025Review
- Visceral Leishmaniasis in Immunocompetent Hosts in Brescia: A Case Series and Analysis of Cytokine Cascade.Microorganisms · 2024Article
- Synthesis of new 3-acetyl-1,3,4-oxadiazolines combined with pyrimidines as antileishmanial and antiviral agents.Molecular diversity · 2023Article
- Impetiginous Cutaneous Leishmaniasis after COVID-19 Infection in a Patient with Poor Cardiac Profile: A Case Report and Literature Review.Tropical medicine and infectious disease · 2023Article
- Co-infection of COVID-19 and parasitic diseases: A systematic review.Parasite epidemiology and control · 2023Review
- The Impact of COVID-19 Pandemic on Arthropod-Related Diseases.Journal of arthropod-borne diseases · 2023Review
- Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology.PloS one · 2023Article
- Third Case of Visceral Leishmaniasis in COVID-19: Mini Review Article.Pathogens (Basel, Switzerland) · 2022Review
- Severe visceral leishmaniasis and COVID-19 coinfection in an immunosuppressed patient.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Article
- Protozoan co-infections and parasite influence on the efficacy of vaccines against bacterial and viral pathogens.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the COVID-19 pandemic spreads across the globe, it will undoubtedly cross paths with long endemic infectious diseases in different areas. Interactions between SARS-CoV2 and well-known pathogens will likely give rise to unfamiliar clinical presentations, depending on complex and as yet unknown immunological interactions. We present a case of coinfection with COVI19 and visceral leishmaniasis and discuss recent reports regarding coexistence of SARS-CoV2 and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.